Please assess the completion status of the following clinical trial:

Trial Title: Imexon for Relapsed Follicular and Aggressive Lymphomas

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosis:~   Group 1: Histologically confirmed indolent NHL, including follicular (any grade), small lymphocytic lymphoma, marginal zone lymphoma and lymphoplasmacytic lymphomaGroup 2: histologically confirmed diffuse large B-cell, mantle cell, Burkitt, Burkitt-like, and diffuse large B-cell transformed from indolent non-Hodgkin's lymphoma.~2. Prior treatment:~   Group 1: (indolent histologies): Patients must have demonstrated relapsed or refractory disease to 1 prior treatment regimen. The maximum number of prior regimens used for treatment is not specified.~   Group 2: (aggressive histologies): Patients must have demonstrated relapsed or refractory disease to at least 1 prior treatment regimen. In the case of de novo diffuse large B-cell lymphoma, prior treatment must include R-CHOP or R-CHOP-like therapy, as well as second line autologous stem cell transplantation unless the patient is not eligible. The maximum number of prior regimens is not specified.~3. At least one target lesion, measurable by radiographic methods according to the 2007 Revised Response Criteria for Malignant Lymphoma.~4. ECOG Performance Status 0-2.~5. No clinical or laboratory evidence of central nervous system disease.~6. Adult (age 18 years or older).~7. Projected life expectancy \>4 months.~8. If female, neither pregnant (negative pregnancy test required at screening) nor lactating.~9. If of child-bearing potential, must be able to use and agree to use medically acceptable contraception for the duration of the study. For female subjects who are neither post-menopausal nor surgically sterilized, this includes oral or injectable hormonal methods, barrier methods such as an intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence. Male subjects must also agree to use an acceptable method for contraception for the duration of the study.~10. No major infection or serious uncontrolled concomitant disease. Fully recovered from any major surgery.~11. No evidence of other concurrent active malignancy.~12. At least 4 weeks since any prior cancer chemotherapy (2 weeks for corticosteroids), antibody therapy, or radiotherapy.~13. Prior radiotherapy to less than an estimated 25% of the bone marrow. In addition, the target lesion(s) must not have been previously irradiated.~14. Clinical laboratory values within the following limits:~    1. Hgb \>/=10.0 g/dL~   2. Absolute neutrophil count ANC \>/=1,500/mm3~   3. Platelets \>/=75,000/mm3~   4. Serum creatinine \</=2.0 times upper limit of normal~   5. Serum bilirubin \</=2.0 times upper limit of normal~   6. Serum AST and ALT \</=3 times upper limit of normal~15. G6PD level \>/= lower limit of normal~16. Able and willing to render informed consent and to follow protocol requirements.~Exclusion Criteria:~1. Diagnosis of lymphoma based on fine needle aspirate.~2. Curative therapy is indicated or possible.~3. Absence of a measurable target lesion, or the only target lesion was previously irradiated.~4. Symptoms, exam findings, or laboratory findings to suggest central nervous system disease involvement.~5. Age \< 18 years~6. Projected life expectancy \<4 months.~7. Pregnant or lactating.~8. Unable or unwilling to use medically acceptable contraception, if of childbearing potential.~9. Evidence of major infection or other serious uncontrolled concomitant illness. Not fully recovered from prior major surgery.~10. Evidence of other active malignancy.~11. Prior radiotherapy, antibody therapy, or cancer chemotherapy within 4 weeks before start of treatment (2 weeks for corticosteroids). Prior radiotherapy to \>25% of the bone marrow.~12. Clinical laboratory values outside of permitted ranges.~13. Respiratory insufficiency requiring oxygen therapy; angina at rest, or myocardial infarction in previous 3 months; history of life threatening ventricular arrhythmia; uncompensated CHF or NYHA Grade 3 or 4 cardiac disease.~14. Unable or unwilling to give informed consent and to follow protocol requirements.~15. Failure to meet any of the eligibility criteria.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Imexon (Type: EXPERIMENTAL): Subjects will be treated on Days 1-5 of 21-day treatment cycles for up to one year. Following pre-treatment with anti-emetics Amplimexon will be given by intravenous infusion over 60 minutes.

Based on this trial design, predict the completion outcome and termination type (if applicable).